Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.

Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J.

Chest. 2009 May;135(5):1293-300. doi: 10.1378/chest.08-1160.

2.

Lymphatic involvement in lymphangioleiomyomatosis.

Glasgow CG, Taveira-Dasilva AM, Darling TN, Moss J.

Ann N Y Acad Sci. 2008;1131:206-14. doi: 10.1196/annals.1413.018. Review.

3.

Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.

Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, Tominaga S, Fukuchi Y.

Lymphat Res Biol. 2006;4(3):143-52.

PMID:
17034294
4.

Involvement of lymphatics in lymphangioleiomyomatosis.

Glasgow CG, Taveira-DaSilva A, Pacheco-Rodriguez G, Steagall WK, Tsukada K, Cai X, El-Chemaly S, Moss J.

Lymphat Res Biol. 2009 Dec;7(4):221-8. doi: 10.1089/lrb.2009.0017.

5.

The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM).

Xu KF, Zhang P, Tian X, Ma A, Li X, Zhou J, Zeng N, Gui YS, Guo Z, Feng R, Zhang W, Sun W, Cai B.

Respir Med. 2013 Feb;107(2):263-8. doi: 10.1016/j.rmed.2012.10.006.

6.

Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases.

Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ, Franz DN, McCormack FX.

Chest. 2010 Sep;138(3):674-81. doi: 10.1378/chest.10-0573.

7.

Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis.

Radzikowska E, Jaguś P, Sobiecka M, Chorostowska-Wynimko J, Wiatr E, Kuś J, Roszkowski-Śliż K.

Respir Med. 2015 Nov;109(11):1469-75. doi: 10.1016/j.rmed.2015.09.005.

PMID:
26386638
8.

Lymphatic manifestations of lymphangioleiomyomatosis.

Gupta R, Kitaichi M, Inoue Y, Kotloff R, McCormack FX.

Lymphology. 2014 Sep;47(3):106-17. Review.

PMID:
25420303
9.

Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses.

Hayashi T, Kumasaka T, Mitani K, Okada Y, Kondo T, Date H, Chen F, Oto T, Miyoshi S, Shiraishi T, Iwasaki A, Hara K, Saito T, Ando K, Kobayashi E, Gunji-Niitsu Y, Kunogi M, Takahashi K, Yao T, Seyama K.

Hum Pathol. 2016 Apr;50:34-42. doi: 10.1016/j.humpath.2015.11.002.

PMID:
26997436
10.

Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis.

Chang WY, Cane JL, Blakey JD, Kumaran M, Pointon KS, Johnson SR.

Respir Res. 2012 Apr 18;13:34. doi: 10.1186/1465-9921-13-34.

11.

Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.

Taveira-DaSilva AM, Jones AM, Julien-Williams P, Shawker T, Glasgow CG, Stylianou M, Moss J.

Chest. 2015 Oct;148(4):1027-33. doi: 10.1378/chest.15-0456.

12.

Role of serum vascular endothelial growth factor D in discrimination of patients with polycystic lung diseases.

Radzikowska E, Jaguś P, Skoczylas A, Sobiecka M, Chorostowska-Wynimko J, Wiatr E, Kuś J, Roszkowski-Śliż K.

Pol Arch Med Wewn. 2013;123(10):533-8.

13.

Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis.

Kumasaka T, Seyama K, Mitani K, Sato T, Souma S, Kondo T, Hayashi S, Minami M, Uekusa T, Fukuchi Y, Suda K.

Am J Surg Pathol. 2004 Aug;28(8):1007-16.

PMID:
15252306
14.

Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.

Cai X, Pacheco-Rodriguez G, Haughey M, Samsel L, Xu S, Wu HP, McCoy JP, Stylianou M, Darling TN, Moss J.

Chest. 2014 Jan;145(1):108-12. doi: 10.1378/chest.13-1071.

15.

Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis.

Glasgow CG, El-Chemaly S, Moss J.

Eur Respir Rev. 2012 Sep 1;21(125):196-206. doi: 10.1183/09059180.00009311. Review.

16.

Lymphangioleiomyomatosis: a disease involving the lymphatic system.

Seyama K, Kumasaka T, Kurihara M, Mitani K, Sato T.

Lymphat Res Biol. 2010 Mar;8(1):21-31. doi: 10.1089/lrb.2009.0018. Review.

PMID:
20235884
17.

Lymphatic manifestations of lymphangioleiomyomatosis.

Gupta R, Kitaichi M, Inoue Y, Kotloff R, McCormack FX.

Lymphology. 2014 Sep;47(3):106-17.

PMID:
25507287
18.

Extrapulmonary lymphangioleiomyomatosis presented as the asymptomatic retroperitoneal tumours--two cases report.

Słodkowska J, Patera J, Breborowicz J, Jarzemska A, Korzeniewska-Kosela M, Siemiatkowska K, Radzikowska E, Przybylski G, Kozłowski W.

Pol J Pathol. 2006;57(4):205-7.

PMID:
17285764
19.

Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium.

Issaka RB, Oommen S, Gupta SK, Liu G, Myers JL, Ryu JH, Vlahakis NE.

Am J Pathol. 2009 Oct;175(4):1410-20. doi: 10.2353/ajpath.2009.080830.

20.

Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis.

Taveira-DaSilva AM, Moss J.

Clin Epidemiol. 2015 Apr 7;7:249-57. doi: 10.2147/CLEP.S50780. Review.

Items per page

Supplemental Content

Support Center